Trial Profile
GEIS-27: Phase I/II Multicenter and Prospective Trial of Nilotinib and Adriamycin as Neoadjuvant Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 30 Jul 2018
Price :
$35
*
At a glance
- Drugs Doxorubicin (Primary) ; Nilotinib (Primary)
- Indications Chondrosarcoma; Leiomyosarcoma; Liposarcoma; Sarcoma
- Focus Therapeutic Use
- Acronyms GEIS-27
- 23 Jul 2018 From January 2012 to April 2013, 13 patients were assessed for eligibility to the phase I portion of the trial. The clinical cut-off date for the final analyses of the phase II part (in this portion only retroperitoneal liposarcomas or leiomyosarcomas were enrolled ) will be in October 2018, according to results published in the Clinical Cancer Research.
- 23 Jul 2018 Results (n=13) of phase 1 part published in the Clinical Cancer Research.
- 14 Sep 2015 New trial record